A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID, cc-5013) (IND 73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory

Trial Profile

A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID, cc-5013) (IND 73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700028982,700057042, 70059082) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top